CHICAGO, Ill.—November 7, 2003— Organ Recovery Systems, a developer of technologies and services to improve the quality and quantity of organs, cells, and tissues for transplantation, announced today that its LifePort™ Kidney Transporter has been chosen by the editors of Popular Science as one of this year’s top 100 breakthrough technologies in the 16th annual Best of What’s New (BOWN) Awards. The LifePort Kidney Transporter received the Award in the Personal Health category and is featured with other winners in the magazine’s December issue.

The LifePort Kidney Transporter is the first in a new generation of mobile perfusion devices designed specifically to establish a continuum of organ care that spans the critical time between recovery and transplantation. The LifePort Kidney Transporter is a portable, durable, and fully automated medical device that assesses and treats donated kidneys by perfusing or gently pumping the organ with a solution as a pre-treatment for transplantation. The LifePort™ perfusion device provides a new high-tech alternative to the conventional static method of organ storage and transportation—a cooler filled with ice.

“The LifePort Kidney Transporter has been chosen to receive a 2003 Best of What’s New Award from Popular Science,” said Editor-in-Chief Scott Mowbray. “Each year, we review thousands of new products and innovations and choose just 100 winners in twelve categories for inclusion in our annual Best of What’s New issue. To win, a product or technology must represent a significant step forward in its category.”

“Organ Recovery Systems, its partners, and all who labored to make the LifePort a reality take great pride in the recognition from a highly regarded publication like Popular Science. This validation brings full circle the creative inspiration sparked by the publication over the years,” said Organ Recovery Systems CEO David Kravitz. “We are making significant progress in applying this innovative technology platform to develop LifePort devices for the heart, liver and pancreas.”

The LifePort Kidney Transporter gently perfuses, or pumps, the kidney with a cold liquid solution to improve its condition before transplantation. Research shows that machine perfusion can safely prolong the average cold storage time for kidneys from the current 18-24 hours to 48 hours or more. With the extra time afforded by this technology, kidney transplants may soon become more elective-style as opposed to emergency-style procedures, which could help in improve outcomes and decrease hospital costs. LifePort is designed for perfusion transport between donor hospitals, organ procurement organizations (OPOs), and transplant centers, both within a regional service area or across the country. The device also provides critical data to monitor and evaluate kidneys during transport. As a result, physicians and organ procurement professionals can better ensure a proper match between donor and recipient. Perhaps most important, perfusion technology enables better opportunity to recover more organs such as those from expanded criteria and nonheartbeating donors whose organs are not otherwise considered.

About Popular Science
POPULAR SCIENCE® is published by Time4 Media®, the world’s leading publisher of leisure-time magazines. Founded in 1872, POPSCI is the world’s largest science and technology magazine, with a circulation of 1.45 million subscribers and a readership of more than seven million people. Time4 Media® is a subsidiary of Time Inc., which is a wholly owned subsidiary of Time Warner Inc. (NYSE: TWX).

About Organ Recovery Systems
Organ Recovery Systems is a privately held company developing technologies and services to improve the quality and quantity of organs, tissues, and cells for transplantation. The company’s flagship medical device is the FDA-cleared LifePort™ Kidney Transporter, the first in a new generation of mobile perfusion devices specifically designed to establish a continuum of organ care that spans the critical time between recovery and transplantation. Organ Recovery Systems is organized into three operating groups: the Perfusion Services Group helps leading transplant centers and organ procurement organizations (OPOs) by employing proprietary perfusion techniques for evaluation and therapy of traditional, expanded criteria, and nonheartbeating donor kidneys prior to transplant; the Medical Devices Group develops perfusion-based devices to improve the preservation, assessment, and treatment of organs for transplantation; and the Charleston Research Center develops new technologies for cell and tissue preservation and evaluation while conducting basic and applied research to support the company’s platform of organ therapy products. For more about Organ Recovery Systems visit http://www.organ-recovery.com.

Your Privacy | Legal Notes | info@proseedcapital.com